Samsara Vision Begins SING IMT PERSPECTIVE Trial

Samsara Vision has officially launched its PERSPECTIVE clinical trial, marking a significant step forward in the evaluation of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT) for pseudophakic patients, those who have previously undergone cataract surgery with intraocular lens (IOL) implantation.

The first surgical procedure under the study was successfully performed on September 30, 2025, by Dr. John Conrath, vitreoretinal and cataract surgeon at Centre Monticelli-Paradis in Marseille, France.

“Implanting the SING IMT in pseudophakic patients is just the beginning—structured visual rehabilitation is critical also for patients to adapt to their new vision,” said Dr. Conrath. “Through PERSPECTIVE, we aim to better understand how surgery and training together can restore meaningful function to patients with late-stage AMD.”

Expanding Indications for Advanced AMD Care

The PERSPECTIVE trial is currently underway in three CE referenced countries where the SING IMT is already approved. It represents the first multicenter, randomized study to evaluate the device in pseudophakic eyes, an off-label patient group currently contraindicated for the device.

The trial is designed to assess:

• Safety and visual performance post-implantation

• Patient selection criteria

• Rehabilitation protocols

• Potential for expanded access to late-stage age-related macular degeneration (AMD) patients

Addressing an Unmet Need

“Most older adults experience immense benefits from routine cataract surgery with an intraocular lens implant,” said Thomas Ruggia, CEO and president of Samsara Vision. “However, individuals with co-existing AMD who advance to late-stage disease with central vision loss do not experience the same vision benefits from IOLs. Central vision restoration for these patients is a huge unmet medical need. We’re excited to advance the PERSPECTIVE clinical trial to generate meaningful data to inform a possible label expansion so that we can offer our sight-enhancing device to many patients in CE referenced countries.”

The PERSPECTIVE study is expected to enroll participants through 2026.